Subscription to raise £900,000 to progress proprietary TYK2/JAK1 programmes through final stages of preclinical development
Cambridge, UK, 1 June 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that it has raised £900,000, before expenses, through a subscription by a high net worth individual (the “Subscriber”) for 32,142,855 new ordinary shares of 0.025p each in the capital of the Company (“Ordinary Shares”) (the “Subscription Shares”) at a price of 2.8p per share (the “Subscription Price”) (the “Subscription”).
The Subscriber will also be issued one five-year warrant, exercisable at the Subscription Price, for every five Subscription Shares issued (the “Subscription Warrant”), which can only be exercised following the Company’s the closing middle market share price being above 5p per Ordinary Share for five consecutive days. The Subscription Price represents a premium of approximately 8 per cent. to the closing middle market price for Sareum Shares on 28 May 2021.
The net proceeds from the Subscription will be used to progress the Company’s SDC-1801 TYK2/JAK1 inhibitor drug development programmes as well as for working capital purposes. As noted in the Company’s Trading Update of 25 May 2021, the Company is targeting the completion of these preclinical studies in Q3 2021, subject to successful progress. Clinical trial plans, including priority autoimmune indications and potential Covid-19 application, will also be developed in parallel, subject to additional funding being raised.
Application will be made for the 32,142,855 Subscription Shares, which will rank pari passu with the Company’s existing Ordinary Shares, to be admitted to trading on the AIM market of the London Stock Exchange (“AIM”) (“Admission”). It is anticipated that Admission will become effective at 8.00 am on 11 June 2021. The Placing is subject to normal conditions including, inter alia, Admission.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following the above issue of equity, the issued share capital of the Company will comprise 3,302,865,651 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Dr Tim Mitchell, CEO of Sareum Holdings plc, said: “The Subscription will enable us to continue advancing our lead internal TYK2/JAK1 inhibitor programme, SDC-1801, through its final preclinical studies. We are targeting the completion of these studies in Q3 2021 and are finalising our plans for the initial clinical trials.
“This Subscription, together with any further funds raised and grants awarded to Sareum, will also help us to further explore the potential benefit of SDC-1801 against Covid-19 and TYK2/JAK1 inhibitor SDC-1802 against cancers.
“We look forward to keeping investors informed on our progress and to providing further updates during the year.”
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.
SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned